Two medicines, side by side
Enalapril vs valsartan
Enalapril and valsartan are both labeled for high blood pressure and heart failure. Drugs@FDA records approvals of enalapril since 1985 and of valsartan since 1996. Pharmacies paid $0.0664 per enalapril maleate 10 mg tablet and $0.0963 per valsartan 40 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, enalapril is an angiotensin converting enzyme inhibitor and valsartan an angiotensin 2 receptor blocker.
Check it at the source: the enalapril FDA label on DailyMed (effective January 23, 2026); the valsartan FDA label on DailyMed (effective August 5, 2026).
Highlights of the enalapril record
Enalapril (Vasotec) · label of January 23, 2026
FETAL TOXICITY See full prescribing information for complete boxed warning.
When pregnancy is detected, discontinue VASOTEC ® as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS, Fetal Toxicity ).
Used for
From the label: indicationsHypertension VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive. Heart Failure VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. […]
On the market
- Earliest approval on file
- December 24, 1985
- Generic labelers
- 28 labelers
- Pharmacy cost
- $0.0664 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 17
Highlights of the valsartan record
Valsartan (Diovan) · label of August 5, 2026
FETAL TOXICITY
When pregnancy is detected, discontinue valsartan tablets as soon as possible. ( 5.1 )
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue valsartan tablets as soon as possible. ( 5.1 ).
Used for
From the label: indicationsValsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: • Hypertension, to lower blood pressure in adults and children 6 years and older. […]
On the market
- Earliest approval on file
- December 23, 1996
- Generic labelers
- 34 labelers
- Pharmacy cost
- $0.0963 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 58
Source: FDA drug labels via openFDA (Enalapril label of January 23, 2026, Valsartan label of August 5, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do enalapril and valsartan differ on the record?
In FDA's classes, enalapril is an angiotensin converting enzyme inhibitor and valsartan an angiotensin 2 receptor blocker.
How each works, in its label's words: Enalapril, “Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.”; Valsartan, “Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).”
Half-life, in each label's words: Enalapril, “The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours.”; Valsartan, “Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination …”
Both labels carry a boxed warning; the records quote them.
Generics: enalapril since 2000; valsartan since 2014 (Drugs@FDA).
| Enalapril | Valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | High blood pressure, Heart failure |
| Pharmacologic class | Angiotensin Converting Enzyme Inhibitor | Angiotensin 2 Receptor Blocker |
| How it works (label) | Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. | Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). |
| Half-life (label) | The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours. | Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. |
| Earliest approval on file (Drugs@FDA) | December 24, 1985 | December 23, 1996 |
| First generic approved | August 22, 2000 | June 26, 2014 |
| Generic labelers (NDC) | 28 labelers | 34 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0664 per tablet (Enalapril maleate 10 mg tablet) | $0.0963 per tablet (Valsartan 40 mg tablet) |
| 12-month price change | -12% | -21% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 17 | 58 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 60,702 | 104,490 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to enalapril
- every medicine labeled for the same conditions